title: Developmental therapeutics in childhood cancer. A perspective from the Children's Oncology Group and the US Food and Drug Administration.
abstract: Drug development in pediatric oncology has been reviewed, concentrating on overall development issues and COG studies of cytotoxic compounds. A variety of interesting molecules with more specific targeting are becoming available. The challenges that remain include the availability of such compounds for pediatric trial and their study in a timely fashion, and the subsequent incorporation of the new agents into more up-front regimens, with the ultimate shared goal of curing more children with less toxicity.
authors.affiliation: Service of Hematology-Oncology, Sainte-Justine Hospital, Department of Pediatrics, University of Montreal, Montreal, Québec, Canada.
authors.forename: M L
authors.initials: ML
authors.lastname: Bernstein
authors.forename: G H
authors.initials: GH
authors.lastname: Reaman
authors.forename: S
authors.initials: S
authors.lastname: Hirschfeld
mesh_terms: D000293:Adolescent; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D017321:Clinical Trials, Phase I as Topic / Q000331:legislation & jurisprudence* / Q000592:standards; D015195:Drug Design; D004992:Ethics, Medical; D005568:Forms and Records Control; D006801:Humans; D007223:Infant; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D020714:Maximum Tolerated Dose; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D018579:Patient Selection; D012449:Safety; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic